Naloxone, commonly known by the brand name Narcan, is an opioid-receptor blocker that can reverse opioid overdoses. This easy ...

Naloxone (also known as Narcan, the commonly used drug to treat narcotic overdoses) has greater binding to opioid receptors ...

However, it is only able to occupy pain receptors for 30 to 90 minutes. For more potent opioids, such as fentanyl, that may not be long enough. To determine how the naloxone companion drug, which ...

Naloxone (orange) treats opioid overdose by kicking out opioids (pink) from the opioid receptor (teal). The newly discovered compound 368 (purple) strengthens the binding of naloxone to the opioid ...

Naloxone, which is given as a nasal spray or injection, works by seizing opioid receptors, kicking out opioids and taking their place. (Naloxone has no addictive properties of its own.) The ...

One side effect of naloxone is intense symptoms of opioid withdrawal, but although compound 368 enhances most of naloxone’s actions, it does not seem to enhance withdrawal symptoms.

Further experiments in cells revealed that, in the presence of compound 368, naloxone was 7.6 times more effective at inhibiting the activation of the opioid receptor, partly because naloxone ...

However, the action of naloxone only lasts about 2 hours before it detaches from the receptor, allowing longer-lasting opioid molecules, such as fentanyl, which can remain in the bloodstream for 8 ...

NOTES: (1) Naloxone is less effective in saving people who have overdosed on fentanyl because fentanyl binds more tightly than heroin to opioid receptors in the brain, so it is more difficult for ...

Naloxone is a safe, easy-to-use, life-saving medication that blocks the effects of opioids. Naloxone is an opioid receptor antagonist that can be given through injection or nasal spray.

News Opioid antidote naloxone now available in drug stores The life-saving nasal spray, sold under the brand names Narcan and RiVive, can be purchased over the counter for about $44 to $50 ...

Brandy Schillace’s review of “Candace Pert” by Pamela Rykman (Bookshelf, Nov. 15) contains a questionable conclusion: the discovery of the mu opioid receptor in 1972 “helped launch the ...